We Understand the Value of Strong Collaborations
For the U.S. and EU markets, we are seeking a pharmaceutical industry partner for Imeglimin for the Phase 3 clinical development program and commercialization. In Japan, China and other Asian countries, Sumitomo Dainippon Pharma is our strategic partner for Imeglimin. For Japan, Poxel and Sumitomo Dainippon Pharma will jointly conduct the Phase 3 program, which will be funded by Sumitomo Dainippon Pharma, and Sumitomo Dainippon Pharma will commercialize Imeglimin for this market. In China, South Korea, Taiwan and nine other Southeast Asian countries including Indonesia, Vietnam, Thailand, Malaysia, the Philippines, Singapore, Myanmar, Cambodia, and Laos, Sumitomo Dainippon Pharma will be solely responsible for the development and commercialization of Imeglimin.
We collaborate on an ongoing basis with academic leaders in metabolic disease, cardiovascular disease and mitochondrial dysfunction.
We have entered into a licensing agreement with Enyo Pharma based in Lyon, France, granting Enyo access to our FXR (farnesoid X receptor) agonist. Enyo has advanced this program into a Phase 1 study for Hepatitis B.
Our Academic Collaborators
- CarMeN Laboratoire de recherche Cardiovasculaire, Métabolisme, Diabétologie et Nutrition, Université Lyon UMR INSERM 1060, France
- INSA Lyon, Hospices Civils
- Yale University, New Haven, CT, USA
- Université de Rouen UMR INSERM 1096, France
- Kobe University, Japan
- Université de Grenoble U1042 & UMR_S 1055, France
Our Industry Collaborators
- Merck Serono
- Enyo Pharma
- Sumitomo Dainippon Pharma
Interested in Collaborating with Us?
We'd love to hear from you and discuss partnership opportunities.